Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment: Complete Statistical AnalysisIndependent statistical analysis of RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RAD001 Plus Bevacizumab in Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of RAD001 Plus Bevacizumab in Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00591734).
- RAD1801Independent statistical analysis of RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Radial Reload Laparoscopic LAR Case Series: Complete Statistical AnalysisIndependent statistical analysis of Radial Reload Laparoscopic LAR Case Series: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01706822).
- RADIANTA detailed statistical analysis and educational interpretation of the RADIANT phase 3 trial of erlotinib versus placebo after surgery in EGFR-positive non-small cell lung cancer, focusing on disease-free survival and time-to-event methodology.
- Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Radiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the Breast: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the Breast: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Radiation Therapy to Treat Musculoskeletal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy to Treat Musculoskeletal Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00186992).
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Radiosurgery for Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Radiosurgery for Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00456612).
- Radiotherapy for Solid Tumor Spine Metastases: Complete Statistical AnalysisIndependent statistical analysis of Radiotherapy for Solid Tumor Spine Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01752036).
- RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers: Complete Statistical AnalysisIndependent statistical analysis of RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- RAINBOIndependent statistical analysis of the RAINBO phase 2/3 trial of molecularly guided adjuvant treatment strategies in endometrial cancer, including trial design, recurrence-free survival endpoints, planned statistical analysis, and interpretation.
- Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion: Complete Statistical AnalysisIndependent statistical analysis of Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion:…
- Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma: Complete Statistical AnalysisIndependent statistical analysis of Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC): Complete Statistical AnalysisIndependent statistical analysis of Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size…
- Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy: Complete Statistical AnalysisIndependent statistical analysis of Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy: Complete Statistical AnalysisIndependent statistical analysis of Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02203695).
- Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs: Complete Statistical AnalysisIndependent statistical analysis of Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs: primary endpoint results, effect estimate…
- RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS: Complete Statistical AnalysisIndependent statistical analysis of RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00126672).
- Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2: Complete Statistical AnalysisIndependent statistical analysis of Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rasburicase in Patients at Risk for Tumor Lysis Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Rasburicase in Patients at Risk for Tumor Lysis Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00628628).
- Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436: Complete Statistical AnalysisIndependent statistical analysis of Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534897).
- Re-expression of ER in Triple Negative Breast Cancers: Complete Statistical AnalysisIndependent statistical analysis of Re-expression of ER in Triple Negative Breast Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01194908).
- Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size…
- REACH 5Independent statistical analysis of Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant: primary endpoint results, effect estimate with confidence…
- REACTComplete statistical analysis of the REACT phase 3 trial of two years of adjuvant celecoxib versus placebo in primary breast cancer, including trial design, disease-free survival, overall survival, statistical methodology, and interpretation.
- READYComplete statistical analysis of the READY phase 3 trial of docetaxel plus dasatinib versus docetaxel plus placebo in castration-resistant prostate cancer, including trial design, overall survival, secondary endpoints, statistical methodology, safety, and…
- Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study: Complete Statistical AnalysisIndependent statistical analysis of Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients – A Multi Center Chart Review: Complete Statistical AnalysisIndependent statistical analysis of Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review:…
- REAL-2Independent statistical analysis of REAL-2 (NCT06956976), a randomized parallel-group trial comparing preservation versus dissection of No. 253 lymph nodes during robotic resection for mid/low rectal cancer.
- Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor: Complete Statistical AnalysisIndependent statistical analysis of Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05361655).
- Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy: Complete Statistical AnalysisIndependent statistical analysis of Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04176354).
- Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01928030).
- RECORD-4Independent statistical analysis of Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01491672).
- Rectal Spacer for Prostate Cancer Radiation Image Guidance: Complete Statistical AnalysisIndependent statistical analysis of Rectal Spacer for Prostate Cancer Radiation Image Guidance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05650021).
- REDIRECTIndependent statistical analysis of Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence…
- Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease: Complete Statistical AnalysisIndependent statistical analysis of Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease: primary endpoint results, effect…
- Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers: Complete Statistical AnalysisIndependent statistical analysis of Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Reducing Metabolic Syndrome Among Breast Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Reducing Metabolic Syndrome Among Breast Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03719677).